During the darkest years of the HIV/AIDS epidemic, access to lifesaving medication became one of the defining struggles for people living with the virus. In the United States, where healthcare has long been shaped by private insurance, market forces, and unequal access, desperate patients often turned to underground “buyers clubs” to obtain experimental or unaffordable HIV drugs. In Australia, meanwhile, the Pharmaceutical Benefits Scheme (PBS) evolved into a very different model — one based on government subsidy, negotiated pricing, and universal access principles.

The contrast between America’s HIV buyers clubs and Australia’s PBS highlights two fundamentally different healthcare philosophies: one driven largely by the marketplace, the other by public health policy.

The Rise of HIV Buyers Clubs in America

In the early 1980s, HIV/AIDS spread rapidly through gay communities in major American cities such as New York and San Francisco. Fear, stigma, and political indifference compounded the crisis. At the time, there were no approved treatments, and patients faced almost certain death.

The United States healthcare system offered little security for many HIV-positive people. Insurance coverage was inconsistent, experimental medications were difficult to access, and many patients were financially devastated by illness. Government agencies such as the FDA were criticised for moving too slowly while thousands died.

Out of this desperation emerged the HIV buyers clubs.

Buyers clubs were underground or semi-legal organisations that sourced experimental drugs, unapproved treatments, vitamins, and alternative therapies from overseas manufacturers or sympathetic suppliers. These clubs operated largely outside traditional pharmaceutical and regulatory systems.

One of the most famous was the San Francisco Buyers Club, founded by activists determined to help people access treatments before official approval. Similar organisations appeared across the United States. Some imported drugs from Mexico, Europe, or Asia. Others distributed compounds still undergoing clinical trials.

For many patients, buyers clubs represented hope when mainstream medicine seemed paralysed. They became lifelines for people abandoned by government institutions and priced out of conventional healthcare.

These clubs also reflected the anger and activism of the HIV community. AIDS activists believed patients facing terminal illness should have the right to try experimental therapies, even if regulators considered them unsafe or unproven. The slogan “Drugs into bodies” became a rallying cry.

However, the buyers club phenomenon also exposed the dangers of inequality. Access often depended on geography, connections, or financial means. Some treatments distributed through clubs later proved ineffective or harmful. Patients, driven by desperation, sometimes became vulnerable to misinformation, false hope, or exploitation.

Yet despite these flaws, buyers clubs forced change. Activism surrounding them pressured the FDA to accelerate drug approvals and expand compassionate access programs. They helped reshape the relationship between patients, regulators, and pharmaceutical companies in America.

Australia’s PBS: A Different Approach

Australia’s experience with HIV treatment developed within a vastly different healthcare structure.

The Pharmaceutical Benefits Scheme, established in 1948, was designed to ensure Australians could access essential medicines at affordable prices regardless of personal wealth. Under the PBS, the government negotiates directly with pharmaceutical companies and subsidises approved medications.

When HIV treatments began emerging in the late 1980s and early 1990s, Australia incorporated many of them into the PBS system. This meant eligible Australians could obtain HIV medication at heavily subsidised prices rather than facing catastrophic private costs.

The PBS became one of Australia’s most important public health protections during the HIV epidemic.

Unlike the United States, Australia’s healthcare system reduced the need for underground medication networks. HIV-positive Australians generally accessed treatment through hospitals, clinics, and government-supported programs rather than informal buyers clubs.

Australia also benefited from a stronger partnership between public health officials, clinicians, and community organisations. Harm reduction strategies, public education campaigns, and relatively early engagement with affected communities helped shape a more coordinated national response.

This does not mean Australia’s response was perfect. HIV stigma certainly existed, particularly during the 1980s. Some patients still faced discrimination, fear, and isolation. Access to newer treatments could sometimes lag behind the United States due to regulatory processes and pricing negotiations.

However, the existence of the PBS fundamentally altered the experience of living with HIV in Australia. Medication costs were not left entirely to market forces or private insurers. The government assumed responsibility for ensuring broad public access.

Two Systems, Two Philosophies

The comparison between American buyers clubs and Australia’s PBS reveals a deeper divide in healthcare philosophy.

In America, healthcare largely functions as a commercial system where access often depends on insurance, employment, or financial resources. During the AIDS crisis, this structure left many patients vulnerable. Buyers clubs emerged because official systems failed to provide timely, affordable access to treatment.

In Australia, the PBS reflected a belief that essential medicine should be treated as a public good rather than a luxury commodity. While not immune from political or financial pressures, the PBS reduced the likelihood that critically ill patients would need underground networks to survive.

The American buyers clubs were born from desperation and activism. The PBS was born from public policy and collective healthcare funding.

Ironically, both systems demonstrated the power of community pressure. In America, activists forced authorities to accelerate reform through protest and civil disobedience. In Australia, sustained public support for universal healthcare helped preserve the PBS despite ongoing pressure from some political and corporate interests.

Ongoing Challenges

Even today, the issues raised by both systems remain highly relevant.

In the United States, HIV medications can still cost tens of thousands of dollars annually without adequate insurance coverage. Access to healthcare remains uneven, and debates over pharmaceutical pricing continue.

Australia’s PBS, while widely praised, also faces challenges. Governments continually negotiate with pharmaceutical companies over pricing, and some newer medications remain expensive for taxpayers to subsidise. There are periodic fears that free trade agreements or international patent rules could weaken Australia’s ability to control medicine prices.

Globally, HIV treatment access remains deeply unequal. Millions still struggle to obtain medication in lower-income countries despite the existence of effective therapies.

Legacy of the Buyers Clubs and PBS

The legacy of America’s HIV buyers clubs is one of resistance, activism, and patient empowerment. They represented ordinary people refusing to quietly accept death while bureaucracy delayed action.

The legacy of Australia’s PBS is one of collective healthcare responsibility — the belief that access to medicine should not depend solely on personal wealth.

Both systems emerged from different political cultures, yet both profoundly shaped the lives of people living with HIV.

In many ways, the comparison asks a broader question still debated today: should healthcare primarily operate as a market, or as a human right?

The HIV epidemic forced nations to confront that question under the most tragic circumstances imaginable. The answers America and Australia provided could hardly have been more different.

Tim Alderman ©️ 2026